Evidence map›Paper›PMID 37280571›Full record

ArticleBMC cancer2023

Interleukin-24-mediated antitumor effects against human glioblastoma via upregulation of P38 MAPK and endogenous TRAIL-induced apoptosis and LC3-II activation-dependent autophagy.

Seyedeh Maliheh Babazadeh, Mohammad Reza Zolfaghari, Mohsen Zargar, Kazem Baesi, Sayed Younes Hosseini, Amir Ghaemi

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Interleukin-24: A Multidimensional Therapeutic for Treatment of Human Diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
  10. Identification ofCancer genomics & proteomics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Seyedeh Maliheh BabazadehDepartment of Microbiology, Faculty of Basic Science, Qom Branch, Islamic Azad University, Qom, Iran.
Mohammad Reza ZolfaghariDepartment of Microbiology, Faculty of Basic Science, Qom Branch, Islamic Azad University, Qom, Iran. mreza.zolfaghary@gmail.com.
Mohsen ZargarDepartment of Microbiology, Faculty of Basic Science, Qom Branch, Islamic Azad University, Qom, Iran.
Kazem BaesiHepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, Iran.
Sayed Younes HosseiniBacteriology and Virology Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Amir GhaemiDepartment of Influenza and other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran. ghaem_amir@yahoo.com.
Qom Islamic Azad University · IRPasteur Institute of Iran · IRShiraz University of Medical Sciences · IR

Funding

National Institute for Medical Research Development 962110
6 · The paper itself

Abstract

backgroundMelanoma differentiation-associated gene 7 (Mda-7) encodes IL-24, which can induce apoptosis in cancer cells. A novel gene therapy approach to treat deadly brain tumors, recombinant mda-7 adenovirus (Ad/mda-7) efficiently kills glioma cells. In this study, we investigated the factors affecting cell survival and apoptosis and autophagy mechanisms that destroy glioma cells by Ad/IL-24.

methodsHuman glioblastoma U87 cell line was exposed to a multiplicity of infections of Ad/IL-24. Antitumor activities of Ad/IL-24 were assessed by cell proliferation (MTT) and lactate dehydrogenase (LDH) release analysis. Using flow cytometry, cell cycle arrest and apoptosis were investigated. Using the ELISA method, the tumor necrosis factor (TNF-α) level was determined as an apoptosis-promoting factor and Survivin level as an anti-apoptotic factor. The expression levels of TNF-related apoptosis inducing ligand(TRAIL) and P38 MAPK genes were assessed by the Reverse transcription-quantitative polymerase chain reaction(RT‑qPCR) method. The expression levels of caspase-3 and protein light chain 3-II (LC3-II) proteins were analyzed by flow cytometry as intervening factors in the processes of apoptosis and autophagy in the cell death signaling pathway, respectively.

resultsThe present findings demonstrated that transduction of IL-24 inhibited cell proliferation and induced cell cycle arrest and cell apoptosis in glioblastoma. Compared with cells of the control groups, Ad/IL24-infected U87 cells exhibited significantly increased elevated caspase-3, and TNF-α levels, while the survivin expression was decreased. TRAIL was shown to be upregulated in tumor cells after Ad/IL-24 infection and studies of the apoptotic cascade regulators indicate that Ad/IL-24 could further enhance the activation of apoptosis through the TNF family of death receptors. In the current study, we demonstrate that P38 MAPK is significantly activated by IL-24 expression. In addition, the overexpression of mda-7/IL-24 in GBM cells induced autophagy, which was triggered by the upregulation of LC3-II.

conclusionsOur study demonstrates the antitumor effect of IL-24 on glioblastoma and may be a promising therapeutic approach for GBM cancer gene therapy.

Indexed as

GlioblastomaApoptosisApoptosis Regulatory ProteinsAutophagyCaspase 3Cell Line, TumorHumansInterleukin-24p38 Mitogen-Activated Protein KinasesSurvivinTNF-Related Apoptosis-Inducing LigandTumor Necrosis Factor-alphaUp-RegulationApoptosis Regulatory ProteinsCaspase 3Interleukin-24p38 Mitogen-Activated Protein KinasesSurvivinTNF-Related Apoptosis-Inducing LigandTumor Necrosis Factor-alphaAntitumorAutophagyCell apoptosisGlioblastomaIL-24Recombinant adenovirus

Identifiers

PMID37280571
PMCPMC10242982
OpenAlexW4379537059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.